Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03102437 · ClinicalTrials.gov registry record · NA

Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System

A NA study, sponsored by Impulse Dynamics.

Terminated
Registry status
NA
Development phase
106
Enrollment target

NCT03102437: Clinical Trial NA study, sponsored by Impulse Dynamics.

NCT03102437 is a NA study that was terminated before completion, run by Impulse Dynamics. The registered enrollment target is 106 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03102437, a NA study, was terminated before completion, sponsored by Impulse Dynamics.

TERMINATED
Registry status
NA
Development phase
106 participants
Enrollment target

Study Summary

This is a multicenter, prospective, single-arm Continued Access study of the Optimizer Smart System with CCM therapy.

Primary Outcome

The FIX-HF-5CA Study was unofficially intended to serve as the Post-Approval Study (PAS) with the intention of collecting 3 year observed mortality data and comparing that to the predicted probability of mortality derived from two validated heart failure models \[MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) and SHFM (Seattle Heart Failure Model)\]. The objective was to show that the observed prevalence of mortality was not worse than the derived predicted probability of mortality

Interventions

  • DEVICE Optimizer Smart System

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2017-07-01
Est. Completion 2019-12-16
Phase NA
Impulse Dynamics

9 total trials

Why NCT03102437 stopped before completion

NCT03102437 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 1 intervention - of which Optimizer Smart System is the first listed.

NCT03102437 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03102437 about?

NCT03102437 is a clinical study titled "Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System". This is a multicenter, prospective, single-arm Continued Access study of the Optimizer Smart System with CCM therapy.

What is the current status of trial NCT03102437?

This trial is currently terminated. It is a NA study. The enrollment target is 106 participants. The study started on 2017-07-01. Estimated completion is 2019-12-16.

What interventions are being tested in trial NCT03102437?

The interventions under investigation include: Optimizer Smart System (DEVICE).

Who is sponsoring clinical trial NCT03102437?

This trial is sponsored by Impulse Dynamics, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03102437's enrollment target sits among peer trials

106 830th of 2000 higher than 1,167 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03181048 · 106 participants · NA

    Clinical Trial of Concomitant Hip Arthroscopy During PAO

  • NCT04682158 · 106 participants · Phase 2

    Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

  • NCT04724018 · 106 participants · Phase 1

    Sacituzumab Govitecan Plus EV in Metastatic UC

  • NCT04798274 · 106 participants · NA

    Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03102437, the US trial registry maintained by the National Library of Medicine. NCT03102437 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.